NasdaqGS:INGN

Stock Analysis Report

Executive Summary

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally.

Snowflake

Fundamentals

Flawless balance sheet and fair value.

Risks

  • Inogen has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Inogen's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-2.6%

NasdaqGS:INGN

-0.08%

US Medical Equipment

0.2%

US Market


1 Year Return

-82.5%

NasdaqGS:INGN

14.1%

US Medical Equipment

-0.7%

US Market

INGN underperformed the Medical Equipment industry which returned 14.7% over the past year.

INGN underperformed the Market in United States of America which returned 0.3% over the past year.


Share holder returns

INGNIndustryMarket
7 Day-2.6%-0.08%0.2%
30 Day-28.1%0.5%-2.7%
90 Day-36.7%10.2%1.6%
1 Year-82.5%-82.5%15.0%14.1%1.6%-0.7%
3 Year-27.3%-27.3%68.4%63.2%40.0%30.9%
5 Year105.4%105.4%131.5%104.9%53.8%36.8%

Price Volatility Vs. Market

How volatile is Inogen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Inogen undervalued based on future cash flows and its price relative to the stock market?

24%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

Inogen's share price is below the future cash flow value, and at a moderate discount (> 20%).

Inogen's share price is below the future cash flow value, but not at a substantial discount (< 40%).


Price Based on Earnings

Inogen is good value based on earnings compared to the US Medical Equipment industry average.

Inogen is overvalued based on earnings compared to the United States of America market.


Price Based on Expected Growth

Inogen is poor value based on expected growth next year.


Price Based on Value of Assets

Inogen is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Inogen expected to perform in the next 1 to 3 years based on estimates from 7 analysts?

14.8%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Inogen's revenue is expected to grow by 9.2% yearly, however this is not considered high growth (20% yearly).

Inogen's earnings are expected to grow by 14.8% yearly, however this is not considered high growth (20% yearly).

Inogen's revenue growth is expected to exceed the United States of America market average.

Inogen's earnings growth is expected to exceed the United States of America market average.

Inogen's earnings growth is expected to exceed the low risk savings rate of 2.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Inogen will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Inogen performed over the past 5 years?

40.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Inogen has delivered over 20% year on year earnings growth in the past 5 years.

Inogen's 1-year earnings growth is less than its 5-year average (30.7% vs 40.6%)

Inogen's earnings growth has exceeded the US Medical Equipment industry average in the past year (30.7% vs 28.9%).


Return on Equity

Inogen has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).


Return on Assets

Inogen used its assets more efficiently than the US Medical Equipment industry average last year based on Return on Assets.


Return on Capital Employed

Inogen's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).


Next Steps

  • Explore strong past performing companies in the Healthcare industry.

Financial Health

How is Inogen's financial position?


Financial Position Analysis

Inogen is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Inogen's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Inogen has no debt.

Inogen has no debt compared to 5 years ago when it was 12%.

Inogen has no debt, it does not need to be covered by operating cash flow.

Inogen has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet

Low level of unsold assets.

Inogen has no debt, it does not need to be covered by short term assets.


Next Steps

Dividend

What is Inogen's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Inogen's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Inogen's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Inogen has not reported any payouts.

Unable to verify if Inogen's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Inogen has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Inogen's salary, the management and board of directors tenure and is there insider trading?

2.6yrs

Average management tenure


CEO

Scott Wilkinson (54yo)

2.4yrs

Tenure

US$2,687,338

Compensation

Mr. Scott Wilkinson has been the Chief Executive Officer of Inogen, Inc. since March 1, 2017 and as its President since January 1, 2016. Mr. Wilkinson served as the Chief Operating Officer of Inogen, Inc.  ...


CEO Compensation Analysis

Scott's remuneration is about average for companies of similar size in United States of America.

Scott's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

2.6yrs

Average Tenure

40yo

Average Age

The tenure for the Inogen management team is about average.


Board Age and Tenure

5.0yrs

Average Tenure

59yo

Average Age

The tenure for the Inogen board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Brenton Taylor (38yo)

    Co-founder & Executive VP of Engineering

    • Tenure: 18.6yrs
    • Compensation: US$929.83k
  • Ali Bauerlein (38yo)

    Co-founder

    • Tenure: 18.6yrs
    • Compensation: US$1.24m
  • Byron Myers (40yo)

    Executive Vice President of Sales & Marketing

    • Tenure: 2.6yrs
    • Compensation: US$928.61k
  • Scott Wilkinson (54yo)

    CEO, President & Director

    • Tenure: 2.4yrs
    • Compensation: US$2.69m
  • Bart Sanford (53yo)

    Executive Vice President of Operations

    • Tenure: 0.9yrs
    • Compensation: US$1.15m
  • Matt Bacso

    Investor Relations & Corporate Development Manager

    • Tenure: 0.0yrs

Board Members

  • R. Greer (61yo)

    Independent Director

    • Tenure: 4.0yrs
    • Compensation: US$240.74k
  • Heath Lukatch (52yo)

    Chairman of the Board

    • Tenure: 11.6yrs
    • Compensation: US$296.24k
  • Richard Casaburi

    Member of Advisory Board

    • Tenure: 0.0yrs
  • Jeffrey Kupperman

    Member of Advisory Board

    • Tenure: 0.0yrs
  • Paul Selecky

    Member of Advisory Board

    • Tenure: 0.0yrs
  • Neil MacIntyre

    Member of Advisory Board

    • Tenure: 0.0yrs
  • Loren McFarland (60yo)

    Independent Director

    • Tenure: 6.6yrs
    • Compensation: US$236.24k
  • Scott Wilkinson (54yo)

    CEO, President & Director

    • Tenure: 2.4yrs
    • Compensation: US$2.69m
  • Robert Chatburn

    Member of Advisory Board

    • Tenure: 0.0yrs
  • Heather Rider (59yo)

    Independent Director

    • Tenure: 5.0yrs
    • Compensation: US$240.24k

Company Information

Inogen, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Inogen, Inc.
  • Ticker: INGN
  • Exchange: NasdaqGS
  • Founded: 2001
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$917.270m
  • Shares outstanding: 21.93m
  • Website: https://www.inogen.com

Number of Employees


Location

  • Inogen, Inc.
  • 326 Bollay Drive
  • Goleta
  • California
  • 93117
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
INGNNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDFeb 2014
6IODB (Deutsche Boerse AG)YesCommon StockDEEURFeb 2014

Biography

Inogen, Inc., a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United S ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/21 01:09
End of Day Share Price2019/08/20 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.